Comparative Study of the Effects of Dry Needling and Botulinum Toxin Type A as a Treatment for Lower Limb Post-stroke Spasticity
Comparative Study of the Mechanism of Action of Dry Needling and Botulinum Toxin Type A as a Treatment for Lower Limb Post-stroke Spasticity: a Proof of Concept Controlled Trial
Universiteit Antwerpen
90 participants
Sep 1, 2024
INTERVENTIONAL
Conditions
Summary
This is a randomized parallel group clinical trial which will be conducted in three countries (Spain, Canada and Belgium) comparing Botulinum Toxin type A (BTX-A) and Dry Needling (DN) effectiveness for post-stroke spasticity in participants who had a first stroke in the previous 12 months and have plantar flexor spasticity. Participants will be randomly allocated to receive either one session of BTX-A or 12 weekly sessions of DN. Blinded evaluators will assess the effects before, during, and after treatment, and at a 4-week follow-up.
Eligibility
Inclusion Criteria7
- aged 18-75 years.
- post-stroke spasticity in ankle plantar flexors (Modified Ashworth Scale (MAS) scores of 1-2).
- first stroke.
- 0-12 months evolution.
- no previous BTX-A or DN treatment for spasticity.
- ankle passive range of motion ≥ 20° (approximately) with knee flexion ~30°.
- independent ambulation with or without aids.
Exclusion Criteria4
- medical conditions interfering with data interpretation.
- contraindications for BTX-A or DN treatment.
- changes in anti-spasticity medication dosage (if appropriate), either during the trial or within the 3 months prior to participation.
- pregnant or breastfeeding.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Botulinum toxin type A injections are a treatment technique to treat the spastic muscles in patients with stroke that targets on the neuromuscular endplate zone provoking a chimical disruption of dysfunctional endplates.
Dry Needling is a treatment technique to treat the spastic muscles in patients with stroke that targets on the neuromuscular endplate zone provoking a mechanical disruption of dysfunctional endplates.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06296082